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Abstract
Parkinson's disease (PD) is a neurodegenerative movement disorder characterized by the
progressive loss of dopaminergic neurons in the substantia nigra and depletion of dopamine in the
striatum, which lead to pathological and clinical abnormalities. Increasing evidence has
demonstrated that inflammation is the fundamental process contributing to neuron death in PD.
Neuroinflammation, which is characterized by activated microglia and infiltrating T cells at sites
of neuronal injury, is a prominent contributor to the pathogenesis of progressive PD. Microglia
play a critical role in forming a self-propelling cycle leading to sustained chronic
neuroinflammation and driving the progressive neurodegeneration in PD. This activation depends
heavily on the respiratory burst within the microglia, which in turn regulates a number of
downstream pro-inflammatory activities. On the other hand, the adaptive immune responses, most
notably T cells, are now emerging as important components of the inflammatory response that
contribute to the pathogenesis of PD. This review paper focus on the understanding of the
inflammatory etiology of PD, as well as the molecular signaling involved in this inflammatory
response, with the aim to provide more effective treatments to slow down or halt the progression
of chronic inflammation-induced CNS disorders, such as PD.
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Parkinson's disease: a chronic inflammatory, progressive
neurodegenerative disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder after
Alzheimer's disease. It is characterized by a slow and progressive degeneration of
dopaminergic (DA) neurons in the substantia nigra (SN) and degeneration of the nerve
terminals in the striatum, which will eventually lead to the development of progressive
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movement disorders, including resting tremor, rigidity, bradykinesia, and gait disturbance
(Jellinger 2001). Epidemiological studies have revealed that most (90%) PD cases are
sporadic and have a late onset (Tanner 2003). About 10% of cases are characterized by early
onset, and these mostly occur in familial clusters (Mizuno et al. 2001). Development of
parkinsonian syndrome in such individuals has been attributed to mutations in several
recently identified genes, including parkin, Leucine-rich repeat kinase 2 (LRRK2), á-
synuclein, PINK-1, or DJ-1 (Polymeropoulos et al. 1997; Sun et al. 2006; Bonifati et al.
2008; Weng et al. 2007; Abou-Sleiman et al. 2003; Jiang et al. 2007). In contrast,
development of idiopathic PD may represent the final outcome of a complex set of
interactions among the innate vulnerabilities of the nigro-striatal DA system, potential
genetic predisposition, and exposure to environmental toxins. Among the environmental
toxins, infectious agents, pesticides and heavy metals have been implicated to be associated
with the development and progression of PD (Mizuno et al. 2001). However, there is now a
growing recognition of the central role of neuroinflammation in the pathogenesis of PD
(McGeer et al. 2001; Hirsch and Hunot 2009).
While the pathogenic mechanisms that ultimately cause PD are still unclear, it is believed
that the progressive nature of PD is characterized by chronic inflammation-induced DA
neurodegeneration within the SN area (Gao and Hong 2008; Bartels and Leenders 2007;
Dauer and Przedborski 2003). It is well documented that microglial activation results in the
loss of DA neurons in patients with PD. The premise of microglial activation in PD has been
supported by the analysis of post mortem brains from PD patients that provides clear
evidence of microglial activation in the SN (Loeffler et al. 1994; Ghosh et al. 2007;
Cicchetti et al. 2002). In the brains of patients with PD, large numbers of human leukocyte
antigen (HLA-DR) and CD11b-positive microglia were found in the SN, a region in which
the degeneration of DA neurons was most prominent (McGeer et al. 1988). In addition,
levels of proinflammatory mediators, including TNFα, IL-1β, IL-6, reactive oxygen species
(ROS), and eicosanoids are elevated in the brains and peripheral blood mononuclear cells
(PBMC) of PD patients (McGeer et al. 1988; Nagatsu et al. 2000; Mogi et al. 1994). Nitrite
(as an indicator for nitric oxide free radicals) in the cerebrospinal fluid, as well as increased
expression of inducible nitric oxide synthase (iNOS) within the SN, has also been found in
PD patients (Qureshi et al. 1995). Consequently, the vast majority of therapeutic attention
directed at inflammation within the CNS in patients with PD has been directed toward
microglial cell activity.
Peripheral inflammation may initiate or contribute to neuroinflammation
and neurodegeneration in the CNS
It is known that peripheral inflammatory response can affect CNS manifestations. For
example, reduced locomotor activity and sickness behaviors caused by fever are attributed to
the activation of the brain during peripheral inflammation (Simard and Rivest 2005).
Previously, it has been shown that injection of the selective dopaminergic neurotoxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) results in chronic neuroinflammation
and progressive neurotoxicity in human (Langston et al. 1999) and monkeys (McGeer et al.
2003). However, the mechanism underlying the progressive nature of the disease remains
unclear. Recently, our group demonstrated that a single systemic administration of
lipopolysaccharide (LPS) results in significant loss of DA neurons beginning at 7-months
post treatment (23% loss of TH-IR neurons) and increasing in severity with time to a 47%
loss at 10-months post treatment (Qin et al. 2007). This delayed and progressive loss of DA
neurons in the SN (over months) recapitulate some of the cardinal features of PD. Results
from our animal study is in consonant with a clinical case report documenting that a patient
displayed PD-related symptoms after accidental peripheral exposure of LPS (Niehaus 2003).
Since it is known that systemically injected LPS cannot readily reach the brain, further
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studies show that pro-inflammatory factors, such as TNFα underlie the mechanism of
systemic LPS-induced DA neurotoxicity (Qin et al. 2007). TNFα produced in the periphery
after systemic LPS administration is transported through BBB to reach brain through a
TNFα-receptor dependent mechanism. Once TNFα reaches the brain, it will initiate a
cascade event by activating TNFα receptors on the microglia, leading to the synthesis of
additional TNFα and other pro-inflammatory factors, creating a persistent and self-
propelling neuroinflammation that drives delayed and progressive loss of DA neurons in the
SN (Fig. 1). Nguyen et al. (2004) also reported that systemic administration of LPS
enhanced motor neuron degeneration in animal models of amyotrophic lateral sclerosis 6
months after LPS injection. Systemic exposure to LPS in the neonate was also shown to
significantly amplify neuronal death associated with ischemic insult (Lehnardt et al. 2003).
The effects of peripheral inflammation on neuron survival may depend upon several factors
such as the brain region examined, length of time investigated to allow cumulative effects,
age of exposure to the inflammagen, presence of systemic TNFα, and severity of the
inflammatory stimuli tested. Thus, it would be interesting to determine epidemiologically
whether there is a link between patients surviving septic shock and the incidence of
neurodegenerative diseases, such as PD.
Role of microglia in neuroinflammation-mediated neurodegeneration
Among the factors produced by inflammatory cells, the release of superoxide by microglia
has been shown to be the predominant factor fueling neurodegeneration, consistent with the
notion that DA neurons have an increased vulnerability to oxidative insults. This evidence
lends additional support to the strong association of microglial activation with progressive
PD (Block et al. 2007; Czlonkowska et al. 1996). Furthermore, we have previously found
that the midbrain encompasses the SN contains 4.5 times more microglia when compared to
the other brain regions (Kim et al. 2000). Understanding the progressive nature of microglia-
mediated neurotoxicity, and the common characteristics/mechanism of microglial activation
in response to several diverse toxins, has significant therapeutic importance for many
neurodegenerative diseases, since inflammation and microglial activation is a common
component of the pathogenesis for multiple neurodegenerative diseases, including
Alzheimer's disease, PD, Huntington's disease, multiple sclerosis, and amyotrophic lateral
sclerosis (Nguyen et al. 2002).
Role of NADPH oxidase and MAC1 in inflammation-induced PD
NADPH oxidase (PHOX), is the major superoxide-producing enzyme of microglia. It is a
multi-component enzyme consisting of a membrane-associated cytochrome b558 (composed
of 2 subunits: gp91phox and p22phox) and the cytosolic components: p47phox, p67phox,
p40phox, and a small GTPase rac2 (Groemping and Rittinger 2005). Upon activation, its
cytosolic subunits will translocate to cellular membrane and form a functional enzyme to
generate superoxide. Increasing evidence has shown that therapy directed against the
oxidative stress response can play a beneficial role in PD (Smith and Zigmond 2003;
Jackson-Lewis and Smeyne 2005), as anti-inflammatory agents which function by the
inhibition of the NADPH oxidase activity can be neuroprotective (Liu et al. 2003; Qian et al.
2006, 2007a). Both in vivo and in vitro studies from our laboratory using PHOX-deficient
mice have clearly demonstrated reduced DA neurotoxicity induced by LPS or MPTP in
PHOX-/- compared to PHOX+/+ wild-type mice (Qin et al. 2004; Gao et al. 2003. In
addition, a pharmacological PHOX inhibitor diphenyliodonium (DPI), also shows potent
DA-neuroprotection in vitro (Qian et al. 2007b). Moreover, PHOX activity also regulates
production of pro-inflammatory cytokines such as TNFα by microglia following LPS
stimulation (Qin et al. 2004), indicating that PHOX not only mediates superoxide
production, but also controls the levels of other pro-inflammatory neurotoxic factors
produced by activated microglia.
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Further studying the up-stream signaling pathways that regulate the PHOX activity, we
found that microglial MAC1 (macrophage antigen complex 1; an adhesion molecule) is
closely linked with PHOX and plays an important role in microglia-mediated neuro-
inflammation and neurotoxicity. We recently reported that microglial MAC1 was
indispensable for the enhanced neurotoxicity induced by LPS, α-synuclein, or MPTP in
neuron-glia cultures (Pei et al. 2007; Hu et al. 2008; Zhang et al. 2007), and MAC1-deficient
mice show more resistance to MPTP-induced DA neurotoxicity in vivo. Furthermore, it was
also reported that NADPH oxidase-generated oxygen free radicals are required for MAC1-
mediated phagocytosis in neutrophils (Coxon et al. 1996). Therefore, the coupling between
MAC1 and NADPH oxidase might be a central mechanism underlying the reactive
microgliosis that mediates immunologic insults and oxidative damage and consequent
progressive neurodegeneration.
Role of T cell in mediating neuroinflammation-induced PD
The CNS has traditionally been considered “immune privileged” and protected through the
blood–brain barrier. However, recent findings indicate that both innate and adaptive immune
systems play critical roles in the pathogenesis of PD (Benner et al. 2008; Olson and Miller
2004). Increasing evidence also demonstrates a role for an adaptive immune response in the
etiology of PD. For example, T cell infiltration has been found in CNS tissues of PD patients
(Miklossy et al. 2006), and adoptively transferred immune splenocytes into MPTP-treated
mice results in significant infiltration into the brain and localization within the inflamed SN
(Benner et al. 2008). In addition, there are reports indicated that nitrated a-synuclein activate
peripheral leukocytes in draining lymphoid tissue (Benner et al. 2008), and mediated
adaptive immune responses in potentiating microglial activation and exacerbating neuronal
death. Th17 cells also might contribute to neurotoxicity through the release of pro-
inflammatory cytokine IL-17, and secretion of granzyme B, a cytolytic enzyme (Kebir et al.
2007). However, whether this inflammation is the consequence or the cause of neuronal
injury is unclear. Recently, Brochard et al. (2009) report that CD4? T cells are cytotoxic in a
MPTP-induced mouse PD model, and invading CD4? T cell-mediated immune response
contributes to DA neuro-degeneration through Fas/FasL pathway. These studies implicate
that the adaptive immune system, similar to the innate immune system, not only respond to,
but also actively participate in the pathogenesis of PD. However, more work need to be done
to determine if and how they will serve as a potential target for therapy in PD.
Strategies for anti-inflammatory therapy in PD
Emerging evidence demonstrates that numerous inflammatory mediators such as TNFα,
PGE2, NO, free radicals, and potentially other products of activated immune cells can also
play a role in the degeneration of nigral dopamine-producing neurons in several models of
PD. Therefore, treatment with anti-inflammatory reagents directed at a number of different
pro-inflammatory targets could also potentially halt or slow disease progression. Indeed, for
example, steroidal anti-inflammatory drugs (SAIDS) such as dexamethasone have been
reported to show neuroprotection against MPTP or LPS-induced toxicity (Kurkowska-
Jastrzebska et al. 1999; Castano et al. 2002). Non-steroidal anti-inflammatory drugs
(NSAIDS) such as aspirin and ibuprofen reduce inflammation by inhibition of COX activity
(Sairam et al. 2003). The use of microglia inhibitor such as minocycline has shown potential
neuroprotection in PD models (Wu et al. 2002; Du et al. 2001). Recently, strategies by
inactivating pro-inflammatory transcription factor NF-KB (Zhang et al. 2010), and
activating the peroxisome proliferator-activated receptor-γ (PPARγ) (Bernardo et al. 2005),
have shown beneficial effects in the modulation of inflammatory responses. Other strategies
including inhibiting ion channels in microglial cells (Thomas et al. 2007) are also the highly
effective treatments against progressive PD in an animal study, suggesting that there are
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several critical loci of activation and regulation that control the complex activation pattern of
microglial cells in PD. Since extensive discussion of the above-mentioned approaches is
beyond the scope of this review, we chose to focus on three relatively new approaches in
anti-inflammatory therapy for PD: (1) the use of endogenous anti-inflammatory cytokines
IL10 or TGFβ1, as well as the use of regulatory T cells (Tregs, which are the major source
of these anti-inflammatory cytokines in vivo), in the resolution of neuroinflammation; (2)
the use of morphinan-related compounds; and (3) the targeting of NF-κB, the major
transcriptional regulator of inflammation.
Therapies using anti-inflammatory cytokines in PD
Failure to adequately resolve acute inflammation will normally lead to the relatively
uncontrolled chronic inflammation seen in neurodegenerative diseases such as PD.
Endogenously, anti-inflammatory cytokines serve as negative-feedback regulators that keep
potentially pathological activation of immune and immune-like cells under control (Strle et
al. 2001; Moore et al. 2001). IL10 and TGFβ1, the two major anti-inflammatory cytokines
produced by Tregs, show potent effects in reducing neurotoxicity induced by either LPS or
MPTP in PD models. IL10 was shown to function through its inhibition of the production of
TNFα, nitric oxide, and extracellular superoxide in microglia cells (Qian et al. 2006). The
potent effects of IL10 in the in vitro PD models are consistent with a recent in vivo report
that showed sustained administration of IL10 in a viral vector significantly protects DA
neuron loss and behavior deficits induced by intra-striatally infused 6-OHDA in a rat PD
model (Johnston et al. 2008). Conversely, numerous in vitro studies have shown TGFβ1 can
protect neurons from cell death induced by glutamate excitotoxicity (Zhu et al. 2002),
chemical hypoxia (Ruocco et al. 1999), apoptosis (Prehn et al. 1994) and oxidative injury
(Prehn et al. 1994), and in vivo studies show that TGFβ suppresses the progression of EAE
(Szczepanik et al. 2005). In addition, recombinant TGFβ delivered intracerebrally or via
virus vectors protects animals against brain injury induced by ischemic (Unsicker and
Krieglstein 2002), excitotoxic (Ruocco et al. 1999), and oxidative stress (Henrich-Noack et
al. 1996). Although TGFβ has been strongly implicated as a neuroprotective factor, the
molecular mechanism underlying its neuroprotection has not been clearly elucidated. Recent
evidence from our laboratory has shown that the neuroprotective effects of IL10 and TGFβ1
are mainly attributed to their ability to inhibit the production of ROS from microglia during
their activation or reactivation, and the molecular mechanisms appear to be through the
inhibition of PHOX activity by preventing the ERK-dependent phosphorylation on p47phox
in microlgia to reduce oxidase activities induced by LPS. The exact role that IL10 and
TGFβ1 play in the physiological regulation of chronic CNS inflammation in PD, and how
they may be used either alone or in synergy to therapeutically treat microglia-mediated
neurotoxicity in PD are yet to be determined.
Therapies using regulatory T cells in PD
Another approach to the directed introduction of anti-inflammatory cytokines is the use of
Treg cells in therapy for PD. Tregs, which are the primary source of IL10 and TGFβ1 in
vivo, are widely recognized as being a major regulatory mechanism which controls both
innate and adaptive immune responses. Consequently, they have significant potential as a
therapy for inducing neuroprotection in PD. Several studies using MPTP-induced PD model
indicate that induction of Tregs response inhibits microglial activation, and promote
neuronal survival (Reynolds et al. 2007, 2009a, b). Recent report also demonstrates that
Tregs can attenuate Th17 cell-mediated nigrostriatal DA neuro-degeneration after MPTP
intoxication (Reynolds et al. 2010). Tregs have been proposed to suppress immune reactivity
through multiple mechanisms, such as release of IL10 and TGFβ1, induction of apoptotic
tolerance, and suppression of metabolic functions in effector cells. In addition, Tregs have
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also been shown to promote neurotrophic factor production from astrocytes (Reynolds et al.
2007; Stone et al. 2009). Conversely, strategies have been used to induce another type of
regulatory T cell, the Th2 cell, which inhibits microglia activation through the production of
IL4 and IL10, and further stimulates the synthesis of GDNF from astrocyte, thereby
conferring beneficial effects against MPTP-induced neuronal death. For example, copaxone,
a polypeptide-based therapy approved for multiple sclerosis patients, is thought to promote
the development of Th2 cells which function to dampen the CNS inflammation through the
release of anti-inflammatory cytokines and neurotrophic factors (Schwartz and Kipnis 2004;
Benner et al. 2004; Angelov et al. 2003. Copaxone-reactive T cells are also neuroprotective
in animal models of ALS and PD (Benner et al. 2004; Angelov et al. 2003). However, the
interplay between regulatory T cells, glial cells, neurons and other infiltrating leukocytes
within the SN is complex and incompletely understood. Therefore, a greater understanding
of the modulation of adaptive immune system, and of the infiltration and regulation of
inflammation by regulatory T cells within the CNS, is necessary for the development of
effective adaptive immune cell-based therapies in PD patients.
Therapies using morphinan-related anti-inflammatory compounds in PD
Morphinans are compounds with structures resembling morphine alkaloid. We have
previously reported that several analogs of morphinans, such as naloxone, naltrexone or
dextromethorphan are potent anti-inflammatory and neuroprotective compounds (Zhang et
al. 2004). Naloxone and naltrexone are non-selective antagonists of the G-protein-coupled
opioid receptors. Dextromethorphan, widely used as a cough suppressant, is a dextrorotatory
morphinan and therefore, shows little affinity in binding to opioid receptors. Mechanistic
studies reveal that neuro-protective effects of both naloxone and dextromethorphan are due
to their anti-inflammatory properties by reducing the over-activity of brain microglia and
thus dampening the degree of inflammation (Block et al. 2007).
Mechanism underlying the anti-inflammatory and neuroprotective effects of morphinans
and its analogs
To search for the binding site mediating the neuroprotective effects of morphinans, we
recently conducted an experiment using both levo-morphine (L-morphine) and its synthetic
stereo-enantiomer, dextro-morphine (D-morphine), an ineffective opioid receptor agonist.
We found that both morphine isomers are equipotent in their anti-inflammatory and
neuroprotective effects against LPS or MPP+-induced DA neurotoxicity in neuron-glia
cultures (Qian et al. 2007a). We also observed similar neuroprotection mediated by
sinomenine, a naturally occurring dextrorotatory morphinan isomer (Qian et al. 2007c). The
neuroprotective potency of morphine is also similar to opioid receptor antagonist naloxone
(Liu et al. 2000a, b). These findings clearly indicate that morphinans bind to a novel site to
exert anti-inflammatory and neuroprotective effects, which is independent of the
conventional opioid receptor pathway. We have now identified that the catalytic subunit of
PHOX activity, gp91phox is a novel binding site for morphinans (preliminary data). By
binding to the gp91phox subunit, morphinans inhibit the activity of PHOX and reduce the
production of superoxide and dampen the subsequent release of other pro-inflammatory
factors (Qian et al. 2007a).
Recently, after screening a series of dextromethorphan analogs, and 3-hydroxy-morphinan, a
metabolite of dextromethorphan, emerged as an excellent candidate for the treatment of PD.
Studies using primary midbrain neuron-glia cultures showed that 3-hydroxy-morphinan is
more potent in neuroprotection against LPS-induced neurotoxicity than its parent compound
(Zhang et al. 2005). The higher potency of this dextromethorphan analog is attributed to its
neurotrophic effect in addition to the anti-inflammatory effect shared by both
dextromethorphan and 3-hydroxy-morphinan (Zhang et al. 2005). In vivo studies confirmed
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that 3-hydroxy-morphina is more potent than dextromethorphan in protecting DA neurons in
the SN and preventing motor deficits. More significantly, 3-hydroxymorphinan also
attenuated the depletion of striatal levels of dopamine and its metabolites. It is important to
point out that in this study, the neuroprotective effects of 3-hydroxymorphinan were still
observed even when this drug was given after MPTP injections (Zhang et al. 2006). This
finding suggests the possibility that 3-hydroxy-morphinan can be considered not only for the
treatment of PD, but also as a preventive drug.
Therapies targeting pro-inflammatory transcription factor NF-κB in PD
Nuclear transcription factor NF-κB is a family of transcription factors that play an important
role in the regulation of chronic diseases and cancer through the promotion of inflammation
and of cell survival/oncogenesis. Compounds that block the activation of NF-κB are capable
of inhibiting the two major inflammatory pathways in microglia—activation of oxidative
stress and pro-inflammatory cytokine and chemokine production (Anrather et al. 2006;
Gauss et al. 2007; Kim et al. 2006), NF-κB activation is detected within the SN of PD
patients and a PD animal model created by MPTP (Ghosh et al. 2007; Hunot et al. 1997),
and of particular interest is marked colocalization of NF-κB-p65 with CD11b-positive
activated microglia in the SN of postmortem PD brains (Ghosh et al. 2007). These findings
indicate that inflammatory components that are regulated by NF-κB play a significant role
in the pathogenesis of PD. Activation of NF-κB requires the activity of IκB kinase (IKK)
complex, in a manner dependent mainly on the IKK-β catalytic subunit (Karin 1999).
Previous reports have shown that selective inhibition of NF-κB activation using a peptide
against the IKK complex suppressed microglial activation and prevented DA neuronal loss
against MPTP-intoxicated PD mice (Ghosh et al. 2007). Similarly, inhibition of NF-κB
activity is involved in the neuroprotection of pioglitazone (a PPARc agonist) against LPS-
induced DA neurotoxicity (Xing et al. 2007). Recently, a pharmacological inhibitor of IKK-
β generated neuroprotection against LPS-induced toxicity both in vitro and in vivo (Zhang et
al. 2010), and the mechanistic studies using this compound showed that its neuroprotective
effects were mediated by suppressing the activity of NADPH oxidase and the NF-κB
signaling pathway in microglia. Therefore, it appears as though NF-κB is also a strong
potential target for anti-inflammatory therapy in the treatment of PD.
Conclusion
Neuroinflammation, which is characterized by activated microglia and infiltrating T cells at
sites of neuronal injury, is a prominent contributor to the pathogenesis of progressive PD.
Microglia play a critical role in forming a self-propelling cycle leading to sustained chronic
neuroinflammation and driving the progressive neurodegeneration in PD. This activation
depends heavily on the respiratory burst within the microglia, which in turn regulates a
number of downstream pro-inflammatory activities, including NF-κB activation and pro-
inflammatory mediator production. Anti-inflammatory therapies have already been
developed in animal model systems of PD that demonstrate inhibition of the NADPH
oxidase response by microglia is a highly potent and effective approach for inhibiting the
progression of neurodegeneration induced by either a strong pro-inflammatory signal such
as LPS, or even by DA neuron-specific toxins such as MPTP and 6-OHDA. These therapies,
which include direct inhibition of NADPH-mediated ROS production by DPI, or inhibition
of NADPH oxidase activation by anti-inflammatory cytokines, morphinan compounds, or
NF-κB inhibitors, demonstrate that the oxidative stress response by microglia is a key target
for future development of therapies that effectively treat PD. On the other hand, the adaptive
immune responses, most notably T cells, are now emerging as important components of the
inflammatory response that contribute to the pathogenesis of PD. It remains to be
determined how these adaptive immune cells, including Treg, Th2, Th17, or other T cell
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subsets, will serve as effective targets for immune therapy in PD. A further understanding of
the inflammatory etiology of PD, as well as better analysis of the molecular signaling
involved in this inflammatory response, should help to identify these new targets for
immune-based therapy in neurodegenerative disorders such as PD.
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